Biovail Receives Canadian Approval For Ralivia™ For The Treatment Of Moderately Severe Pain Biovail Corporation (NYSE:BVF)(TSX:BVF) announced that it has received an expanded indication for once-daily Ralivia™ - to include the treatment of moderately severe pain in addition to moderate pain - from the Therapeutic Products Directorate (TPD) in Canada. Ralivia™ is now indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more.
Source: www.medicalnewstoday.com20 Per Cent Of GP Cases Could Be Handled By Pharmacists, British Pharmaceutical Conference Pharmacists could help reduce GP workloads by 20 per cent, saving the NHS millions of pounds every year, according to Steve Churton, President of the Royal Pharmaceutical Society of Great Britain (RPSGB).
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
